Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Prostate Cancer

Free Subscription 30.10.2023 1 Br J Cancer 1 Cancer 1 Cancer Lett 1 Clin Med Insights Oncol 5 Eur J Radiol 1 Eur Radiol 3 Eur Urol 2 Int J Radiat Oncol Biol Phys 1 J Magn Reson Imaging 1 J Natl Cancer Inst 1 Oncogene 2 Prostate 3 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Br J Cancer

1. TURPIN A, Delliaux C, Parent P, Chevalier H, et al
   Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
   Br J Cancer. 2023 Oct 24. doi: 10.1038/s41416-023-02449.
   PubMed         Abstract available
   
   

   
   Cancer

2. ISLAMI F, Wiese D, Marlow EC, Kratzer TB, et al
   Progress in reducing cancer mortality in the United States by congressional district, 1996-2003 to 2012-2020.
   Cancer. 2023;129:2522-2531.
   PubMed         Abstract available
   
   

   
   Cancer Lett

3. WANG C, Wang T, Li KJ, Hu LH, et al
   SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrest.
   Cancer Lett. 2023 Oct 23:216464. doi: 10.1016/j.canlet.2023.216464.
   PubMed         Abstract available
   
   

   
   Clin Med Insights Oncol

4. QIAN YH, Shi YT, Sheng XJ, Liao HH, et al
   Evaluating the Role of Morphological Parameters in the Prostate Transition Zone in PHI-Based Predictive Models for Detecting Gray Zone Prostate Cancer.
   Clin Med Insights Oncol. 2023;17:11795549231201122.
   PubMed         Abstract available
   
   

   
   Eur J Radiol

5. ZHANG KS, Neelsen CJO, Wennmann M, Glemser PA, et al
   Same-day repeatability and Between-Sequence reproducibility of Mean ADC in PI-RADS lesions.
   Eur J Radiol. 2023;165:110898.
   PubMed         Abstract available
   
   
6. DEIVASIGAMANI S, Kotamarti S, Adams ES, Seguier D, et al
   Reconciling discordance between PI-RADS 4 lesions and targeted biopsy: Early experience of a multidisciplinary quality improvement protocol with PI-RADS 4 subcategorization.
   Eur J Radiol. 2023;165:110929.
   PubMed         Abstract available
   
   
7. THIJSSEN LCP, de Rooij M, Barentsz JO, Huisman HJ, et al
   Radiomics based automated quality assessment for T2W prostate MR images.
   Eur J Radiol. 2023;165:110928.
   PubMed         Abstract available
   
   
8. URSPRUNG S, Herrmann J, Joos N, Weiland E, et al
   Accelerated diffusion-weighted imaging of the prostate using deep learning image reconstruction: A retrospective comparison with standard diffusion-weighted imaging.
   Eur J Radiol. 2023;165:110953.
   PubMed         Abstract available
   
   
9. AL-MONAJJED R, Radtke JP, Thomas M, Boschheidgen M, et al
   Multiparametric MRI characteristics of prostatitis and atrophy in the peripheral zone in men without prostate cancer.
   Eur J Radiol. 2023;169:111151.
   PubMed         Abstract available
   
   

   
   Eur Radiol

10. NETZER N, Eith C, Bethge O, Hielscher T, et al
    Application of a validated prostate MRI deep learning system to independent same-vendor multi-institutional data: demonstration of transferability.
    Eur Radiol. 2023;33:7463-7476.
    PubMed         Abstract available
    
    

    
    Eur Urol

11. SHARMA AD, Good DW, Alan McNeill S
    Re: Patient-reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
    Eur Urol. 2023 Oct 19:S0302-2838(23)03157-3. doi: 10.1016/j.eururo.2023.
    PubMed        
    
    
12. BOSCHHEIDGEN M, Albers P, Schlemmer HP, Hellms S, et al
    Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
    Eur Urol. 2023 Oct 18:S0302-2838(23)03158-5. doi: 10.1016/j.eururo.2023.
    PubMed         Abstract available
    
    
13. LINDER S, Severson TM, van der Mijn KJC, Nevedomskaya E, et al
    Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.
    Eur Urol. 2023;84:455-460.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

14. FINK CA, Wegener D, Sauer LD, Lentz-Hommertgen A, et al
    Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials.
    Int J Radiat Oncol Biol Phys. 2023 Oct 18:S0360-3016(23)08012.
    PubMed         Abstract available
    
    
15. MOHAMAD O, Zamboglou C, Zilli T, Murthy V, et al
    Safety of ultra-hypofractionated pelvic nodal irradiation in the definitive management of prostate cancer: Systematic Review and Meta-analysis.
    Int J Radiat Oncol Biol Phys. 2023 Oct 18:S0360-3016(23)08006.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

16. ZHANG X, Zhang YD
    Editorial for "Prostate Age Gap: An MRI Surrogate Marker of Aging for Prostate Cancer Detection".
    J Magn Reson Imaging. 2023 Oct 26. doi: 10.1002/jmri.29097.
    PubMed        
    
    

    
    J Natl Cancer Inst

17. HU S, Chang CP, Snyder J, Deshmukh V, et al
    Mental health outcomes in a population-based cohort of patients with prostate cancer.
    J Natl Cancer Inst. 2023 Oct 23:djad175. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Oncogene

18. MILLER KA, Degan S, Wang Y, Cohen J, et al
    PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Oncogene. 2023 Oct 24. doi: 10.1038/s41388-023-02875.
    PubMed         Abstract available
    
    

    
    Prostate

19. FRANCOLINI G, Banini M, Di Cataldo V, Detti B, et al
    PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study.
    Prostate. 2023;83:1201-1206.
    PubMed         Abstract available
    
    
20. HU HP, Anagnostopoulos G, Gouran-Savadkoohi M, Dayes I, et al
    Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers.
    Prostate. 2023 Oct 25. doi: 10.1002/pros.24638.
    PubMed         Abstract available
    
    

    
    Urology

21. DERIGS F, Kowalewski KF, Hartung FO, Waldbillig F, et al
    A Matched-pair Analysis Comparing Systematic Prostate Biopsy by Conventional Transrectal Ultrasound-guidance Versus Software-based Predefined 3D-Guidance.
    Urology. 2023;177:128-133.
    PubMed         Abstract available
    
    
22. CRISOSTOMO-WYNNE T, Lee K, Speir R
    Robot-assisted Laparoscopic Prostatectomy After SpaceOAR Placement.
    Urology. 2023;177:228-229.
    PubMed         Abstract available
    
    
23. VALLI J, Haapiainen H, Murtola TJ, Huhtala H, et al
    Visual Analogue Scale and Expanded Prostate Cancer Index Composite-26 in the Evaluation of Urinary Continence Recovery After Three-Dimensional Laparoscopic Radical Prostatectomy, a Single-Center Prospective Registered Study.
    Urology. 2023;177:103-108.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.